Stomach Neoplasms
Conditions
Keywords
Stomach Neoplasms, phase I/II, Combination chemotherapy, S-1, Docetaxel
Brief summary
This study is an open-label, single center, nonrandomized study, consisting of a dose-escalating phase I study in advanced solid cancer and a subsequent phase II study in metastatic gastric cancer. In phase I study, we aim to determine the MTD and the recommended dose of S-1 combined with docetaxel given every 3 weeks. Dose level and escalating schedule are followings * S-1(level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14) * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) mixed in d5w 200 ml iv over 60 min: Days 1, 8with dexamethasone 8 mg po q 12hr for 3 days (total 6 doses: D0-2)and parenteral pheniramine maleate 1 ample (45.5mg) before docetaxel
Interventions
DRUGS-1, Docetaxel
* Phase I study * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14 * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8 * Phase II study * S-1 (80mg/m2/day) q 12 hours po Days 1-14 * Docetaxel (35 mg/m2) iv : Days 1, 8
Sponsors
National Cancer Center, Korea
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. In phase I:histologically or cytologically confirmed advanced solid Cancer In phase II:histologically or cytologically confirmed metastatic gastric adenocarcinoma 2. Age: over 18 years 3. No prior chemotherapy or radiotherapy (including any adjuvant hemotherapy) in phase II portion Previous chemotherapy up to two regimens (including adjuvant chemotherapy) is allowed in phase I portion; patients are required to have discontinued chemotherapy, immunotherapy, and radiotherapy for at least 4 weeks before entry into phase I portion 4. Disease status must be that of measurable disease defined as: Lesions that can be accurately measured in at least one dimension \>10 mm with spiral CTscan and palpable LN (including supraclavicular LN) in physical examination. 5. Performance status: ECOG 0-2 6. Adequate major organ function including the following Hematopoietic function: WBC\>4,000/mm3 or ANC\> 2,000/mm3, Platelet count ³ 100,000/mm3Hepatic function: Bilirubin UNL (Upper normal limit), AST/ALT levels 2.5X UNL Renal function: Creatinine UNL 7. Patients should sign an informed consent
Exclusion criteria
1. Inadequate cardiovascular function: New York Heart Association class III or IV heart disease Active angina or myocardial infarction within the past 6 monthsHistory of significant ventricular arrhythmia requiring medication with antiarrhythmics or significantconduction system abnormality 2. Other malignancy within the past 3 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix 3. Pregnant or nursing women 4. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy 5. Psychiatric disorder that would preclude compliance 6. Patients receiving a concomitant treatment with drugs interacting with S-1 or docetaxel: flucytosine, phenitoin, warfarin et al.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic | During chemotherapy |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the time to progression and overall survival | During study period |
Countries
South Korea
Outcome results
None listed